Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.56 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | BLVRB | P30043 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 6/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555300 | 1.00 | XDH (0.56) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12816887 | 0.99 | XDH (0.55) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2014546 | 0.95 | XDH (0.56) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12186979 | 0.92 | CDC7 (0.50) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12819579 | 0.91 | XDH (0.55) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL1444276 | 0.89 | XDH (0.53) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2635415 | 0.89 | XDH (0.53) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12186772 | 0.89 | XDH (0.53) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL1356995 | 0.89 | XDH (0.70) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL30254454 | 0.89 | XDH (0.70) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111039891-B | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-109320474-B | Preparation method of febuxostat | 昆明源瑞制药有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-112961119-A | Preparation method of febuxostat impurity | 廊坊师范学院 | 2021-06-15 | — | — | CN | claimed |
| CN-111072591-A | Febuxostat, intermediate and synthesis thereof | 杭州朱养心药业有限公司 | 2020-04-28 | — | — | CN | claimed |
| CN-111039891-A | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2020-04-21 | — | — | CN | claimed |
| WO-2012131590-A1 | AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF | SANDOZ AG (CH) | 2012-10-04 | — | — | WO | claimed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| CN-111072591-B | Febuxostat and intermediates and synthesis thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-111039891-B | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-111039891-B | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119504640-A | Febuxostat preparation technology | 哈药集团技术中心 | 2025-02-25 | — | — | CN | disclosed |
| CN-110824067-B | Method for detecting genotoxic impurities in febuxostat | 天津药物研究院有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-115572272-B | Preparation method of febuxostat and aldehyde ester intermediate thereof | 湖北华世通生物医药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110282069-A1 | HIGH-PURITY FEBUXOSTAT AND THE METHOD FOR PREPARATION | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO/. LTD. (CN) | 2011-11-17 | — | — | US | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011031409-A1 | PROCESSES FOR PREPARING FEBUXOSTAT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031409-A1 | PROCESSES FOR PREPARING FEBUXOSTAT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282069-A1 | HIGH-PURITY FEBUXOSTAT AND THE METHOD FOR PREPARATION | XDH, FIP1L1, FGF23 | XDH 1/4885TARBP2 909/4885ABCC4 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.